Crispr Infuses First Human in Landmark Gene-Editing Study

Crispr Therapeutics and partner Vertex Pharmaceuticals said on Monday morning that the first patient in a trial using CTX001 received the one-time medicine.

Comments

Popular posts from this blog

Coinbase to Ramp Up Web3 Initiatives in the UK as Japan, Dubai Race to Become Blockchain Hubs

Noise Luna Ring Smart Wearable With Heart Rate Monitor, SpO2 Sensor Launched in India: Details

Spotify Raises Premium Plans Prices Across Several Countries